Chembio launches commercial distribution of third-party covid-19 antigen assay

Hauppauge, n.y., aug. 27, 2021 (globe newswire) -- chembio diagnostics, inc. (nasdaq: cemi), a leading point-of-care diagnostics company focused on infectious diseases, today announced its launch of commercial distribution of an fda emergency use authorized, patent pending, rapid point-of-care covid-19 antigen test for use in decentralized and traditional testing settings. product inventory is on-hand and immediately available for shipment to chembio customers across the united states.
CEMI Ratings Summary
CEMI Quant Ranking